ATXI
Avenue Therapeutics, Inc.
Biotechnology
Market Cap$2M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ATXI vs XTLB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$358K
5Y Perf.-50.2%
ATXI vs XTLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ATXI | XTLB |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2M | $358K |
| Revenue (TTM) | $1M | $451K |
| Net Income (TTM) | $-4M | $-1M |
| Gross Margin | 100.0% | 26.4% |
| Operating Margin | -279.8% | -481.6% |
| Total Debt | $0.00 | $138K |
| Cash & Equiv. | $3M | $371K |
ATXI vs XTLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ATXI
XTLB
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Avenue Therapeutics… (ATXI) | 100 | 0.0 | -100.0% |
| XTL Biopharmaceutic… (XTLB) | 100 | 49.8 | -50.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ATXI vs XTLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ATXI and XTLB are tied at the top with 2 categories each — the right choice depends on your priorities. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
ATXI
Avenue Therapeutics, Inc.
The Growth Play
ATXI has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- EPS growth 98.8%
- Lower volatility, beta -0.11, current ratio 3.27x
- Beta -0.11, current ratio 3.27x
Best for: growth exposure and sleep-well-at-night
XTLB
XTL Biopharmaceuticals Ltd.
The Long-Run Compounder
XTLB is the clearest fit if your priority is long-term compounding.
- -84.5% 10Y total return vs ATXI's -100.0%
- -227.7% margin vs ATXI's -266.7%
- -17.7% ROA vs ATXI's -105.8%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATXI | -30.5% revenue growth vs XTLB's -173.2% |
| Quality / Margins | XTLB | -227.7% margin vs ATXI's -266.7% |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATXI | +111.6% vs XTLB's -43.6% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs ATXI's -105.8% |
ATXI vs XTLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLATXILAGGINGXTLB
XTLBXTL Biopharmaceutical…
2leads
ATXIAvenue Therapeutics, …
2leads
6 Total Categories
CATEGORYLEADERvs XTLBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ATXI4/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTLB4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
XTLB5/6
Risk & VolatilityBeta, volatility, and downside exposure
ATXI2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ATXI leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
ATXI is the larger business by revenue, generating $1M annually — 3.1x XTLB's $451,000. Profitability is closely matched — net margins range from -2.3% (XTLB) to -2.7% (ATXI).
| Metric | ATXIAvenue Therapeuti… | XTLBXTL Biopharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $1M | $451,000 |
| EBITDAEarnings before interest/tax | -$4M | -$1M |
| Net IncomeAfter-tax profit | -$4M | -$1M |
| Free Cash FlowCash after capex | -$2M | $0 |
| Gross MarginGross profit ÷ Revenue | +100.0% | +26.4% |
| Operating MarginEBIT ÷ Revenue | -2.8% | -4.8% |
| Net MarginNet income ÷ Revenue | -2.7% | -2.3% |
| FCF MarginFCF ÷ Revenue | -124.1% | -3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +89.1% | +20.0% |
ATXI leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
Evenly matched — ATXI and XTLB each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ATXIAvenue Therapeuti… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Market CapShares × price | $2M | $357,581 |
| Enterprise ValueMkt cap + debt − cash | -$842,479 | $124,581 |
| Trailing P/EPrice ÷ TTM EPS | -0.61x | -0.34x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.79x |
| Price / BookPrice ÷ Book value/share | 3.84x | 0.07x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ATXI and XTLB each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
XTLB leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-161 for ATXI. On the Piotroski fundamental quality scale (0–9), XTLB scores 3/9 vs ATXI's 2/9, reflecting mixed financial health.
| Metric | ATXIAvenue Therapeuti… | XTLBXTL Biopharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -160.6% | -25.5% |
| ROA (TTM)Return on assets | -105.8% | -17.7% |
| ROICReturn on invested capital | — | -54.1% |
| ROCEReturn on capital employed | -9.0% | -50.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$3M | -$233,000 |
| Cash & Equiv.Liquid assets | $3M | $371,000 |
| Total DebtShort + long-term debt | $0 | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -13.31x |
XTLB leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
XTLB leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTLB five years ago would be worth $2,369 today (with dividends reinvested), compared to $1 for ATXI. Over the past 12 months, ATXI leads with a +111.6% total return vs XTLB's -43.6%. The 3-year compound annual growth rate (CAGR) favors XTLB at -12.9% vs ATXI's -80.7% — a key indicator of consistent wealth creation.
| Metric | ATXIAvenue Therapeuti… | XTLBXTL Biopharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -19.8% | +35.4% |
| 1-Year ReturnPast 12 months | +111.6% | -43.6% |
| 3-Year ReturnCumulative with dividends | -99.3% | -33.9% |
| 5-Year ReturnCumulative with dividends | -100.0% | -76.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -84.5% |
| CAGR (3Y)Annualised 3-year return | -80.7% | -12.9% |
XTLB leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
ATXI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ATXI is the less volatile stock with a -0.11 beta — it tends to amplify market swings less than XTLB's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATXI currently trades 56.7% from its 52-week high vs XTLB's 31.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ATXIAvenue Therapeuti… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.11x | 1.71x |
| 52-Week HighHighest price in past year | $0.97 | $10.28 |
| 52-Week LowLowest price in past year | $0.15 | $1.05 |
| % of 52W HighCurrent price vs 52-week peak | +56.7% | +31.6% |
| RSI (14)Momentum oscillator 0–100 | 53.6 | 67.4 |
| Avg Volume (50D)Average daily shares traded | 3K | 2.4M |
ATXI leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ATXIAvenue Therapeuti… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ATXI leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). XTLB leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallAvenue Therapeutics, Inc. (ATXI)Leads 2 of 6 categories
Loading custom metrics...
ATXI vs XTLB: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — ATXI or XTLB?
Over the past 5 years, XTL Biopharmaceuticals Ltd.
(XTLB) delivered a total return of -76. 3%, compared to -100. 0% for Avenue Therapeutics, Inc. (ATXI). Over 10 years, the gap is even starker: XTLB returned -87. 3% versus ATXI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — ATXI or XTLB?
By beta (market sensitivity over 5 years), Avenue Therapeutics, Inc.
(ATXI) is the lower-risk stock at -0. 11β versus XTL Biopharmaceuticals Ltd. 's 1. 71β — meaning XTLB is approximately -1652% more volatile than ATXI relative to the S&P 500.
03Which has better profit margins — ATXI or XTLB?
XTL Biopharmaceuticals Ltd.
(XTLB) is the more profitable company, earning -227. 7% net margin versus -266. 7% for Avenue Therapeutics, Inc. — meaning it keeps -227. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ATXI leads at -279. 8% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — ATXI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — ATXI or XTLB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is ATXI or XTLB better for a retirement portfolio?
For long-horizon retirement investors, Avenue Therapeutics, Inc.
(ATXI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 11)). XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATXI: -100. 0%, XTLB: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between ATXI and XTLB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.